Skip to content
DataLookout
Menu

NCT07036978

Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Start date changed from estimate of May 1, 2026 to May 28, 2026
    • Study description shortened, about 29 words
    • Site details revised
  2. Notable Start date: Aug 1, 2025 to May 1, 2026v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Treatment response classification based on metabolomic profiles
Timeframe: At baseline (prior to treatment initiation) and at first radiographic evaluation (8-12 weeks after treatment initiation).

Secondary (1)

Correlation between immune-microbiome landscape and treatment outcomes

Arms and interventions

Pancreatic Cancer

Surgically Unresectable Pancreatic Cancer

Other: Collecting biospecimens

Sites

1 site in 1 country

  • Linkou Chang Gung Memorial HospitalTaoyuan, Taiwan